

# Joachim Diebold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11438002/publications.pdf>

Version: 2024-02-01

63  
papers

6,281  
citations

125106

35  
h-index

169272

56  
g-index

63  
all docs

63  
docs citations

63  
times ranked

9007  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100162.	0.6	2
2	Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, e13-e15.	0.5	14
3	Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. <i>Current Opinion in Oncology</i> , 2019, 31, 8-12.	1.1	7
4	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 581-588.	1.4	5
5	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	55
6	Human placental growth hormone in ectopic pregnancy: Detection in maternal blood, immunohistochemistry and potential clinical implication. <i>Growth Hormone and IGF Research</i> , 2017, 37, 13-18.	0.5	3
7	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	0.8	277
8	Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, 122-127.	0.5	65
9	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	0.5	141
10	Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, e16-e17.	0.5	25
11	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. <i>PLoS ONE</i> , 2015, 10, e0120299.	1.1	49
12	Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. <i>Lung Cancer</i> , 2015, 89, 104-109.	0.9	69
13	Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. <i>Oncology Research and Treatment</i> , 2015, 38, 560-569.	0.8	5
14	Human placental growth hormone: A potential new biomarker in gestational trophoblastic disease. <i>Gynecologic Oncology</i> , 2015, 136, 264-268.	0.6	9
15	Targeting oncogenic drivers in lung cancer: celebrating a decade of progress. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 81-83.	0.3	1
16	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. <i>Journal of Clinical Oncology</i> , 2015, 33, 992-999.	0.8	326
17	Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer. <i>Cancer Discovery</i> , 2014, 4, 246-257.	7.7	93
18	Assessment of Prostate Cancer With Dynamic Contrast-Enhanced Computed Tomography Using an En Bloc Approach. <i>Investigative Radiology</i> , 2014, 49, 571-578.	3.5	10

#	ARTICLE	IF	CITATIONS
19	Integrated CT-perfusion shows no meaningful correlation with PSA and presurgical Gleason score in patients with early prostate cancer. <i>Clinical Imaging</i> , 2014, 38, 850-857.	0.8	2
20	Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. <i>Lung Cancer</i> , 2013, 82, 365-367.	0.9	32
21	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
22	Detection of ALK-Positive Non-Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1004-1011.	0.5	88
23	A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib. <i>Journal of Thoracic Oncology</i> , 2013, 8, e43-e44.	0.5	101
24	A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib. <i>Journal of Thoracic Oncology</i> , 2012, 7, e23-e24.	0.5	131
25	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E187-96.	3.3	226
26	Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 259-268.	1.4	58
27	Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. <i>Cell Cycle</i> , 2008, 7, 2591-2600.	1.3	725
28	c-MYC Delays Prometaphase by Direct Transactivation of MAD2 and BubR1: Identification of Mechanisms Underlying c-MYC-Induced DNA Damage and Chromosomal Instability. <i>Cell Cycle</i> , 2007, 6, 339-352.	1.3	85
29	Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. <i>European Radiology</i> , 2007, 17, 1898-1905.	2.3	31
30	Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 553-555.	0.8	52
31	KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. <i>Gynecologic Oncology</i> , 2006, 103, 883-887.	0.6	196
32	Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 709-723.	1.2	146
33	6 K-Ras Mutations in Serous Borderline Tumors of the Ovary. <i>Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas</i> , 2005, 4, 357-361.	0.0	0
34	Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 4218-4227.	0.4	272
35	CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. <i>Experimental Cell Research</i> , 2005, 310, 117-130.	1.2	148
36	A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. <i>Journal of Hepatology</i> , 2005, 43, 303-309.	1.8	92

#	ARTICLE	IF	CITATIONS
37	Prostate cancer is characterized by epigenetic silencing of 14-3-3 $\beta$ expression. <i>Oncogene</i> , 2004, 23, 9034-9041.	2.6	83
38	Neoexpression of N-cadherin in E-cadherin positive colon cancers. <i>International Journal of Cancer</i> , 2004, 111, 711-719.	2.3	62
39	K-RAS Mutations in Ovarian and Extraovarian Lesions of Serous Tumors of Borderline Malignancy. <i>Laboratory Investigation</i> , 2003, 83, 251-258.	1.7	44
40	From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7737-7742.	3.3	588
41	Does endometriosis really have premalignant potential? A clonal analysis of laser $\mu$ microdissected tissue. <i>FASEB Journal</i> , 2003, 17, 693-695.	0.2	40
42	Insulin-like Growth Factor-I Receptor and PTEN Protein Expression in Endometrial Carcinoma. <i>American Journal of Clinical Pathology</i> , 2003, 120, 78-85.	0.4	28
43	CAS(Cellular Apoptosis Susceptibility) Gene Expression in Ovarian Carcinoma. <i>American Journal of Clinical Pathology</i> , 2002, 118, 922-929.	0.4	37
44	SCOMP Is Superior to Degenerated Oligonucleotide Primed-Polymerase Chain Reaction for Global Amplification of Minute Amounts of DNA from Microdissected Archival Tissue Samples. <i>American Journal of Pathology</i> , 2002, 161, 43-51.	1.9	73
45	Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. <i>Human Pathology</i> , 2002, 33, 347-354.	1.1	62
46	Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. <i>Nature Genetics</i> , 2002, 31, 301-305.	9.4	220
47	Autofluorescence spectroscopy for the diagnosis of cervical intraepithelial neoplasia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002, 109, 947-951.	1.1	42
48	Cellular Apoptosis Susceptibility Gene Expression in Endometrial Carcinoma: Correlation With Bcl-2, Bax, and Caspase-3 Expression and Outcome. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 359-367.	0.9	76
49	Prognostic Relevance of hMLH1, hMSH2, and BAX Protein Expression in Endometrial Carcinoma. <i>Modern Pathology</i> , 2001, 14, 777-783.	2.9	18
50	Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. , 2000, 88, 2275-2282.		82
51	Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. , 2000, 85, 649-653.		97
52	20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. , 2000, 190, 564-571.		39
53	In vitro-generated stem cell leukaemia showing altered cell cycle progression with distinct signalling of the tyrosine-phosphorylated rasGAP-associated p62dok protein. <i>Journal of Pathology</i> , 2000, 192, 363-372.	2.1	3
54	FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy. <i>Laboratory Investigation</i> , 2000, 80, 1455-1464.	1.7	88

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical Analysis of Drug Resistance-associated Proteins in Ovarian Carcinomas. Pathology Research and Practice, 2000, 196, 469-475.	1.0	34
56	In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 434, 117-120.	1.4	35
57	Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. , 1999, 40, 20-27.		26
58	Microsatellite Analysis in Serous Tumors of the Ovary. International Journal of Gynecological Pathology, 1999, 18, 158-162.	0.9	33
59	Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. , 1999, 40, 20.		1
60	Improvement of Nonradioactive DNA in Situ Hybridization. Biotechnic and Histochemistry, 1998, 73, 228-232.	0.7	5
61	bcl-2 Expression, p53 Accumulation, and Apoptosis in Ovarian Carcinomas. American Journal of Clinical Pathology, 1996, 105, 341-349.	0.4	132
62	Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance. , 1996, 77, 255-264.		195
63	Tissue reactions to cemented hip sockets Histologic and morphometric autopsy study of 25 acetabula. Acta Orthopaedica, 1995, 66, 1-8.	1.4	25